江苏鱼跃医疗设备股份有限公司 独立董事专门会议 2024 年第一次会议决议 一、独立董事专门会议召开情况 2024 年 4 月 19 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"） 以通讯表决的方式召开了独立董事专门会议 2024 年第一次会议。公司于 2024 年 4 月 16 日以书面送达及电子邮件方式发出了召开公司独立董事专门会议 2024 年 第一次会议的通知以及提交审议的议案。全体独立董事共同推举公司独立董事于 春女士任本次会议的召集人并主持本次会议，会议应出席独立董事 3 名，实际出 席会议独立董事 3 名。本次会议的召集、召开及表决等程序符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议决议合法、有效。会议由召集人于 春女士主持，经与会独立董事充分讨论，审议通过了如下议案： 二、独立董事专门会议审议情况 1、关于《公司 2024 年度日常关联交易预计》的议案 满足公司日常经营活动的需要，将遵守公平、公正、公开的原则，按照市场情况 协商确定价格，关联交易定价政策及依据公允，不存在损害公司及投资者利益的 情形。 独立董事专门会议同意本次公司与关联方的日常关联交易预计事项并同意 提交公 ...

Financial Performance - The company's operating revenue for 2023 reached ¥7,971,734,452.47, representing a 12.25% increase from ¥7,101,679,159.74 in 2022[13]. - Net profit attributable to shareholders for 2023 was ¥2,395,853,276.49, a significant increase of 50.21% compared to ¥1,595,037,435.14 in 2022[13]. - The net profit after deducting non-recurring gains and losses was ¥1,835,621,624.25, up 46.79% from ¥1,250,509,076.10 in the previous year[13]. - The basic earnings per share for 2023 was ¥2.41, reflecting a 49.69% increase from ¥1.61 in 2022[13]. - The total assets at the end of 2023 amounted to ¥15,967,458,083.34, which is a 5.78% increase from ¥15,095,211,328.39 at the end of 2022[13]. - The net assets attributable to shareholders increased by 19.31% to ¥11,763,562,138.83 from ¥9,860,018,658.01 in 2022[13]. - The company reported a net cash flow from operating activities of ¥2,126,977,841.98, a decrease of 7.72% compared to ¥2,304,919,408.76 in 2022[13]. - The company achieved total revenue of 7.97 billion yuan in 2023, representing a year-on-year growth of 12.25%[37]. - The net profit attributable to shareholders reached 2.40 billion yuan, an increase of 50.21% compared to the previous year[37]. - The cash flow from operating activities was 2.13 billion yuan, a decrease of 7.72% year-on-year, while accounts receivable decreased by 30.70%[37]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[2]. - The profit distribution plan for 2023 proposes a cash dividend of 8.00 yuan per 10 shares, totaling approximately 801.6 million yuan, which represents 33.46% of the net profit attributable to shareholders[87]. - The total cash dividend amount is fully covered by the company's distributable profits, with no other forms of cash distribution planned[127]. Governance and Compliance - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons and accounting heads[2]. - All board members attended the meeting to review the annual report, ensuring collective responsibility for its content[2]. - The company has a comprehensive governance structure in place, as detailed in the governance section of the report[4]. - The company is committed to enhancing its governance and operational standards, ensuring compliance with relevant laws and regulations[88]. - The company has established internal control systems for foreign exchange hedging to ensure compliance with legal requirements and protect shareholder interests[65]. - The company has established a dedicated meeting system for independent directors to enhance governance[140]. Market and Industry Outlook - Jiangsu Yuyue Medical Equipment Co., Ltd. is positioned in the rapidly growing Chinese medical device market, which is the second largest globally, driven by factors such as GDP growth and an aging population[22]. - The medical device industry in China is expected to grow significantly due to factors such as GDP growth, rising consumer spending, and an aging population[72]. - The industry is undergoing consolidation, with increasing market concentration as regulations tighten and support for leading domestic companies is emphasized[72]. - The overall demand for medical devices is less affected by macroeconomic conditions, indicating a stable growth trajectory for the industry[22]. Research and Development - The company invested 5.04 billion yuan in R&D, accounting for 6.33% of total revenue, while total expenses increased by only 0.23%[39]. - The company is committed to increasing R&D investment to drive innovation and product upgrades, ensuring high-quality medical products and services to meet growing market demands[78]. - The company is expanding its product line with multiple new glucose monitoring devices, enhancing market competitiveness[52]. - The company is developing a new high-flow humidification therapy device for hospital use, which is currently in R&D[51]. - The company has a total of 1,031 R&D personnel in 2023, a decrease of 9.32% from 1,137 in 2022[53]. Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years[12]. - The company is focusing on three core business areas: respiratory therapy, diabetes care, and infection control, while actively incubating high-potential businesses such as emergency care and ophthalmology[74]. - The company aims to expand its international market presence by tailoring its medical device offerings to the specific needs of different countries and regions, leveraging strategic partnerships to enhance competitiveness[76]. - The company is enhancing its marketing strategies to improve online market share and operational efficiency, focusing on both online and offline channels to boost sales performance[76]. Risk Management - The management discussed potential risks and challenges faced by the company in the industry, emphasizing the importance of investor awareness regarding investment risks[2]. - The company recognizes the importance of risk management and will strengthen its internal risk control systems to address potential challenges arising from regulatory compliance and operational processes[78]. Employee and Management Structure - The total number of employees at the end of the reporting period is 6,114, with 2,735 in the parent company and 3,379 in major subsidiaries[118][119]. - The company emphasizes a performance culture that links total compensation to job value and performance, aiming to attract and retain talent[122]. - The company has a structured management system with independent personnel files and compensation systems, separate from the controlling shareholder[90]. - The company is dedicated to talent development, building a high-quality R&D team to foster innovation and maintain competitive advantages in the medical device sector[77]. Environmental and Social Responsibility - The report highlights the company's commitment to environmental and social responsibilities[5]. - The company donated thousands of medical-grade oxygen machines to rural healthcare institutions in impoverished areas, supporting social responsibility initiatives[144]. - The company has implemented a smart energy management system to reduce energy consumption and enhance resource utilization, contributing to its "dual carbon" strategy[142]. Financial Stability and Investments - The company has maintained a strong financial position, with a current ratio of 2.5, indicating good liquidity and financial health[103]. - The company has entrusted RMB 2.935 billion in bank financial products, with no overdue amounts or impairment provisions reported[164]. - The company has completed the acquisition of 100% equity in Beai Ni Environmental Technology (Shanghai) Co., Ltd., which is now included in the consolidated financial statements[135].

Financial Performance - Revenue for the first quarter of 2024 was RMB 2,231,209,294.86, a decrease of 17.44% compared to the same period last year[3] - Net profit attributable to shareholders of the listed company was RMB 659,412,768.43, a decrease of 7.58% year-on-year[3] - Total operating income decreased to 2,231,209,294.86 RMB, down by 17.44% year-over-year[15] - Operating profit for the first quarter of 2024 was RMB 777.03 million, a decrease from RMB 865.19 million in the same period last year[16] - Net profit attributable to the parent company's owners was RMB 659.41 million, compared to RMB 713.52 million in the previous year[16] - The company's total comprehensive income for the quarter was RMB 658.07 million, compared to RMB 708.00 million in the same period last year[16] - Basic earnings per share for the quarter were RMB 0.6619, down from RMB 0.7186 in the same period last year[16] Cash Flow - Net cash flow from operating activities was RMB 675,553,263.28, down 17.14% compared to the same period last year[3] - Cash flow from operating activities was RMB 675.55 million, down from RMB 815.33 million in the prior year[17] - Cash flow from investing activities showed a net outflow of RMB 28.30 million, an improvement from a net outflow of RMB 1.55 billion in the previous year[17] - Cash flow from financing activities had a net outflow of RMB 199.52 million, compared to a net outflow of RMB 370.68 million in the same period last year[18] - Total cash and cash equivalents at the end of the period were RMB 7.64 billion, up from RMB 3.64 billion in the previous year[18] - Net cash flow from investment activities increased by 98.18% year-on-year, mainly due to the company's investment in Chongqing Ant Consumer Finance Co., Ltd. and the purchase of structured deposits in the same period last year[7] Assets and Liabilities - Total assets at the end of the reporting period were RMB 16,599,651,823.63, an increase of 3.96% compared to the end of the previous year[3] - Total assets increased to 16,599,651,823.63 RMB, up by 3.96% compared to the previous period[13] - Total current assets at the end of the period amount to 10,078,070,805.88 RMB, up from 9,385,155,178.47 RMB at the beginning of the period[12] - Long-term receivables at the end of the period are 654,332,861.49 RMB, unchanged from the beginning of the period[12] - Total liabilities decreased to 4,013,294,011.01 RMB, down by 0.95% compared to the previous period[13] - Total equity increased to 12,586,357,812.62 RMB, up by 5.63% compared to the previous period[14] Accounts Receivable and Inventory - Accounts receivable at the end of the reporting period increased by 97.39% compared to the beginning of the period, mainly due to an increase in reasonable receivables within the credit period generated by normal business activities[6] - Accounts receivable at the end of the period amount to 884,734,318.76 RMB, up from 448,210,952.92 RMB at the beginning of the period[12] - Inventory at the end of the period is 1,197,429,569.07 RMB, down from 1,412,311,882.61 RMB at the beginning of the period[12] Income and Expenses - Other income increased by 512.00% year-on-year, mainly due to an increase in government subsidies received during the reporting period[6] - Financial expenses decreased by 4519.01% year-on-year, mainly due to an increase in interest income from bank time deposits and a decrease in loan interest expenses[6] - Cash received from tax refunds increased by 58.14% year-on-year, mainly due to an increase in export tax refunds from export business[6] - Operating costs decreased to 1,584,225,003.71 RMB, down by 14.26% compared to the previous year[15] - R&D expenses decreased to 124,450,232.82 RMB, down by 7.97% year-over-year[15] - Financial expenses showed a net income of 50,842,630.47 RMB, primarily due to higher interest income[15] - Other income increased significantly to 156,252,340.07 RMB, up by 511.89% year-over-year[15] - Credit impairment losses increased to -25,356,963.05 RMB, up by 65.68% compared to the previous year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 53,675[8] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of the shares, totaling 245,983,450 shares[8] - Wu Guangming, an individual shareholder, holds 10.32% of the shares, totaling 103,438,537 shares[8] - Wu Qun, another individual shareholder, holds 7.72% of the shares, totaling 77,389,840 shares, with 58,042,380 shares under restricted sale conditions[8] - Hong Kong Securities Clearing Company Ltd. holds 3.52% of the shares, totaling 35,239,310 shares[8] Monetary Funds and Exchange Rate Impact - The total monetary funds at the end of the period amount to 7,648,128,210.89 RMB, an increase from 7,215,419,322.83 RMB at the beginning of the period[12] - The impact of exchange rate changes on cash and cash equivalents increased by 104.24% year-on-year, mainly due to fluctuations in the US dollar exchange rate during the reporting period[7] Sales and Payments - Sales revenue from goods and services was RMB 2.02 billion, a decrease from RMB 2.66 billion in the previous year[17] - Payments for goods and services were RMB 675.39 million, down from RMB 768.02 million in the prior year[17]

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-051 江苏鱼跃医疗设备股份有限公司 2023 年职工代表大会第二次会议决议 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次会议召开及出席情况 江苏鱼跃医疗设备股份有限公司（以下简称"公司"）职工代表大会于 2023 年 11 月 24 日在公司会议室召开，应出席本次会议的职工代表 150 名，实际出席本次会议的 职工代表 150 名，经会议讨论，一致同意并通过如下决议： 李旭东先生：1970年出生，大专学历，1991 年毕业于华中理工大学工业自动化专 业。曾任职富士康科技(昆山)公司，担任自动化部门主管，2018 年入职苏州鱼跃医疗科 技有限公司，现任公司监事、自动化部高级总监。 李旭东先生未直接持有公司股份，通过参与江苏鱼跃医疗设备股份有限公司-2021 年度第一期员工持股计划、江苏鱼跃医疗设备股份有限公司-2023 年度员工持股计划间 接持有公司股份，与持有公司百分之五以上股份的股东、实际控制人及公司其他董事、 监事、高级管理人员之间无关联关系，不存在《公司法》、《江苏鱼跃医疗设备 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-049 江苏鱼跃医疗设备股份有限公司 第六届监事会第一次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 公司于 2023 年 11 月 14 日以书面送达及电子邮件形式向公司全体监事发出 了召开公司第六届监事会第一次会议的通知。会议于 2023 年 11 月 24 日以通讯 表决的方式召开，会议应到监事 7 人，实到监事 7 人。本次会议的召集、召开符 合《中华人民共和国公司法》（以下简称"《公司法》"）和《江苏鱼跃医疗设备股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 会议由公司监事会主席吕英芳先生主持，经与会监事充分讨论，审议了如下议案。 二、监事会会议审议情况 1、关于《选举公司第六届监事会主席》的议案 选举吕英芳先生（简历附后）为公司第六届监事会主席，任期至第六届监事 会期满为止，自监事会批准之日起生效。 表决结果：同意：7 票；反对：0 票；弃权：0 票 三、备查文件 1、第六届监事会第一次会议决议 特此公告。 江 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-050 2023年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票方式、网络投票方式 3、会议召开时间： 江苏鱼跃医疗设备股份有限公司 现场会议时间：2023年11月24日下午13:30 网络投票时间：2023年11月24日 通过深圳证券交易所交易系统进行网络投票的时间为2023年11月24日9:15~9:25， 9:30~11:30，13:00~15:00； 通过深圳证券交易所互联网投票系统投票的时间为2023年11月24日上午9:15至下午 3:00期间的任意时间。 4、召开地点：江苏省丹阳市河阳生命科学产业园鱼跃医疗1号楼会议室 5、主持人：公司董事长、总经理吴群先生。 6、本次会议的召开符合《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》《深圳证券交易所股票上市规则 ...

上海市通力律师事务所 关于江苏鱼跃医疗设备股份有限公司 2023 年第二次临时股东大会的法律意见书 致: 江苏鱼跃医疗设备股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏鱼跃医疗设备股份有限公司(以下 简称"公司")的委托, 指派本所陈理民律师、赵伯晓律师(以下简称"本所律师")根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》等法律法规和 规范性文件(以下统称"法律法规")及《江苏鱼跃医疗设备股份有限公司章程》(以下简称 "公司章程")的规定就公司 2023 年第二次临时股东大会(以下简称"本次股东大会")相 关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有签 署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有效 的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-048 江苏鱼跃医疗设备股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 1、关于《选举公司第六届董事会董事长》的议案 同意选举吴群先生（简历附后）为公司第六届董事会董事长，任期至第六届 董事会期满为止，自董事会批准之日起生效。 表决结果：同意：9 票；反对：0 票；弃权：0 票 2、关于《选举公司第六届董事会专门委员会成员》的议案 审计委员会委员由于春女士、钟明霞女士、陈建军先生担任，其中，于春女 士担任审计委员会主任； 提名委员会委员由钟明霞女士、万遂人先生、王瑞洁女士担任，其中，钟明 霞女士担任提名委员会主任； 薪酬委员会委员由万遂人先生、于春女士、吴群先生担任，其中，万遂人先 2023 年 11 月 24 日，江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医 疗"或"公司"）以通讯表决的方式召开了第六届董事会第一次会议。公司于 2023 年 11 月 14 日以书面送达及电子邮件方式发出了召开公司第六 ...

1、关于《设立公司2023年度员工持股计划管理委员会》的议案 根据《江苏鱼跃医疗设备股份有限公司2023年度员工持股计划》和《江苏鱼 跃医疗设备股份有限公司2023年度员工持股计划管理办法》（以下简称"《管理 办法》"）的有关规定，本次员工持股计划设立管理委员会，代表持有人统一管 理员工持股计划，监督员工持股计划的日常管理，代表持有人行使股东权利。管 理委员会由3名委员组成，设管理委员会主任1人，管理委员会委员的任期为本次 员工持股计划的存续期。 表决结果：同意9,960万份，占出席持有人会议的持有人所持份额总数的100%； 反对0份，占出席持有人会议的持有人所持份额总数的0%；弃权0份，占出席持有 人会议的持有人所持份额总数的0%。 江苏鱼跃医疗设备股份有限公司（以下简称"公司"）2023年度员工持股计划 第一次持有人会议（以下简称"会议"）于2023年11月22日以通讯表决的方式召开， 会议由公司董事、董事会秘书王瑞洁女士主持。本次会议应出席持有人145人， 实际出席持有人145人，代表公司2023年度员工持股计划（以下简称"本次员工持 股计划"）份额9960万份，占本次员工持股计划总份额的92.4%。本 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-046 江苏鱼跃医疗设备股份有限公司 关于 2023 年度员工持股计划首次受让部分非交易过户完成 的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告中的 虚假记载、误导性陈述或重大遗漏承担责任。 江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）于 2023 年 9 月 12 日召开第五届董事会第二十五次临时会议和第五届监事会第十一次临 时会议，于 2023 年 9 月 28 日召开 2023 年第一次临时股东大会，审议通过了《公 司 2023 年度员工持股计划（草案）及其摘要》等相关议案。具体内容详见公司 于 2023 年 9 月 13 日和 2023 年 9 月 29 日披露在《证券时报》及巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》的相关规定，现将公 司 2023 年度员工持股计划（以下简称"本次员工持股计划"）实施进展情况公告 如下： 一、员工持股计划基本情况 （ ...